Clinical Value Analysis of Pemetrexed Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer

Objective: To analyze the clinical value of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC). Methods: Sixty-nine patients in Shengli Oilfield Central Hospital were recruited between May 2021 and August 2022 and separated into the observation group (n = 35) and the control group (n = 34). Cisplatin combined with pemetrexed (the observation group) and cisplatin combined with gemcitabine (the control group) were used for treatment, respectively, and the therapeutic effects of the two groups were compared. Results: There was no significant difference in the disease control rate between the two groups (P > 0.05); the immune function indexes of the patients in the observation group were significantly higher than those in the control group after treatment (P < 0.05); there was no significant difference in the incidence of nausea and vomiting as well as hair loss (P > 0.05), but the incidence of blood toxicity in the observation group was significantly lower than that in the control group (P < 0.05). Conclusion: Pemetrexed plus cisplatin in NSCLC patients has an ideal effect, and it can improve the quality of life of patients and reduce adverse reactions, which has clinical promotion value.